These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32513905)

  • 1. Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using
    Sharma R; Inglese M; Dubash S; Lu H; Pinato DJ; Sanghera C; Patel N; Chung A; Tait PD; Mauri F; Crum WR; Barwick TD; Aboagye EO
    J Nucl Med; 2020 Dec; 61(12):1743-1748. PubMed ID: 32513905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of [
    Li S; Peck-Radosavljevic M; Ubl P; Wadsak W; Mitterhauser M; Rainer E; Pinter M; Wang H; Nanoff C; Kaczirek K; Haug A; Hacker M
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1732-1741. PubMed ID: 28555333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).
    Ma W; Jia J; Wang S; Bai W; Yi J; Bai M; Quan Z; Yin Z; Fan D; Wang J; Han G
    Theranostics; 2014; 4(7):736-44. PubMed ID: 24883123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
    Contractor K; Challapalli A; Tomasi G; Rosso L; Wasan H; Stebbing J; Kenny L; Mangar S; Riddle P; Palmieri C; Al-Nahhas A; Sharma R; Turkheimer F; Coombes RC; Aboagye E
    Phys Med Biol; 2012 Jun; 57(11):3419-33. PubMed ID: 22572708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
    Chen G; Ma DQ; He W; Zhang BF; Zhao LQ
    World J Gastroenterol; 2008 Oct; 14(37):5738-43. PubMed ID: 18837093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation.
    Cascales-Campos PA; Ramírez P; Lopez V; Gonzalez R; Saenz-Mateos L; Llacer E; Sánchez Bueno F; Robles R; Pons JA; Capel A; Frutos L; Navarro JL; Muñoz-Ramon P; Parrilla P
    Transplant Proc; 2015 Oct; 47(8):2374-6. PubMed ID: 26518931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
    Kaufmann S; Schulze M; Spira D; Horger M
    Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results.
    Cascales Campos P; Ramirez P; Gonzalez R; Febrero B; Pons JA; Miras M; Sanchez Bueno F; Robles R; Parrilla P
    Transplant Proc; 2011; 43(6):2213-5. PubMed ID: 21839236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
    Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of intravoxel incoherent motion (IVIM) imaging in response assessment of hepatocellular carcinoma after transarterial chemoembolization (TACE) - A prospective study.
    Reddy Bursapalle M; Valakkadaa J; Ayappan A
    Radiologia (Engl Ed); 2024; 66(1):23-31. PubMed ID: 38365352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
    Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
    J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
    Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
    Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.